Atractylochromene Is a Repressor of Wnt/β-Catenin Signaling in Colon Cancer Cells

Ah-Ram Shim1,†, Guang-zhi Dong1,†, Hwa Jin Lee2 and Jae-Ha Ryu1,*

1Research Center for Cell Fate Control and College of Pharmacy, Sookmyung Women’s University, Seoul 140-742, 2Department of Natural Medicine Resources, Semyung University, Jecheon 390-711, Republic of Korea

Abstract

Wnt/β-catenin signaling pathway was mutated in about 90% of the sporadic and hereditary colorectal cancers. The abnormally activated β-catenin increases the cancer cell proliferation, differentiation and metastasis through increasing the expression of its oncogenic target genes. In this study, we identified an inhibitor of β-catenin dependent Wnt pathway from rhizomes of Atractylodes macrocephala Koidzumi (Compositae). The active compound was purified by activity-guided purification and the structure was identified as 2,8-dimethyl-6-hydroxy-2-(4-methyl-3-pentenyl)-2H-chromene (attractylochromene, AC). AC suppressed β-catenin/T-cell factor transcriptional activity of HEK-293 reporter cells when they were stimulated by Wnt3a or inhibitor of glycogen synthase kinase-3β. AC down-regulated the nuclear level of β-catenin through the suppression of galectin-3 mediated nuclear translocation of β-catenin in SW-480 colon cancer cells. Furthermore, AC inhibits proliferation of colon cancer cell. Taken together, AC from A. macrocephala might be a potential chemotherapeutic agent for the prevention and treatment of human colon cancer.

Key Words: Atractylochromene, Wnt/β-catenin, Colon cancer, Proliferation

INTRODUCTION

Colorectal cancer is one of the most common cancers in the world and accounts for approximately 10% of all cancer related deaths (Jemal et al., 2011). It has been reported that Wnt/β-catenin signaling pathway is mutated about 90% in the sporadic and hereditary colorectal cancers (Miyaki et al., 1994; Morin, 1999; Fearhead et al., 2001). The mutations cause to stabilize β-catenin protein and increase the nuclear translocation of β-catenin to induce target gene expression (Chen et al., 1995; Kobayashi et al., 2000). It has been reported that regulation of nuclear translocation of β-catenin is regulated by several genes, such as importin/β, nucleoporins, FoxM1 and galectin-3 (Song et al., 2009; Morgan et al., 2014). The nuclear translocated β-catenin interacts with TCF/LEF and other co-transcriptional factors and promoters to express its oncogenic target genes, such as c-Myc, cyclin D1 and survivin, resulting in cancer cell proliferation, metabolism, and survival (He et al., 1998; Tetsu and McCormick, 1999; Zhang et al., 2001). Thus, there is a need for developing new chemotherapeutic agents against colon cancer by inhibition of Wnt/β-catenin signaling pathway.

Galectin-3 is a multifunctional protein and present in nucleus, cytoplasm, surface, and extracellular space of cells. Galectin-3 was reported to be involved in various tumors cells transformation, proliferation, survival, differentiation and metastasis (Inohara et al., 1998; Nangia-Makker et al., 2000; Song et al., 2014). Galectin-3 also has been involved in cancer cell resistance to chemotherapy (Fukumori et al., 2007; Nangia-Makker et al., 2007; Harazono et al., 2014). In colorectal cancer cells, galectin-3 phosphorylates serine 9 residue of glycogen synthase kinase-3β (GSK-3β) to activate Wnt pathway. Galectin-3 also plays important role as a β-catenin binding partner to assist its nuclear accumulation and activates TCF activity through Akt/PI3K pathway (Song et al., 2009).

The rhizomes of Atractylodes macrocephala (Compositae) has been used as a medicinal herb in Korea and China for relaxing pain, digestion and diuretic (Huh, J. (1613) Donguibogam). Diverse pharmacological activities were reported such as anti-inflammatory, anti-tumor, antiulcer, antioxidant, anti-obesity and neuroprotective effects (Mori et al., 1989; Matsuda et al., 1991; Dong et al., 2008; Kim et al., 2009).
2011; Li et al., 2012; Liu et al., 2014). However, there is no study about effects of A. macrocephala on anti-colon cancer. In this study, we isolated an inhibitor of Wnt/β-catenin pathway from rhizomes of A. macrocephala and observed anti-colon cancer activity.

**MATERIALS AND METHODS**

**Reagents**

Rhizomes of A. macrocephala were purchased from Kimi-tongsang (Seoul, Korea) in April 2009 and authenticated by Prof. K. S. Yang at College of Pharmacy, Sookmyung Women’s University. A voucher specimen (No. SPH 09003) was deposited in the herbarium of Sookmyung Women’s University. β-catenin antibody were purchased from BD Transduction Laboratories (San Jose, CA, USA). Galectin-3 antibody was purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). Lamin A/C and cyclin D1 antibodies were purchased from Cell Signaling (Danvers, MA, USA), and β-actin antibody was from Sigma-Aldrich (St Louis, MO, USA). HRP-conjugated goat anti-mouse IgG and goat anti-rabbit IgG was purchased from Enzo Life Science (East Farmingdale, NY, USA). Other chemical reagents including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), were purchased from Enzo Life Science (East Farmingdale, NY, USA). All the primary antibodies were used as a cell-based screening system (Li et al., 2014). After treatment of Wnt3a CM and test sample to the cells for 15 h, TOPFlash reporter activity was determined by measuring firefly luciferase activity. We found that fraction 9 (20 μg/ml) obtained from column chromatography of ethyl acetate extracts showed significant inhibitory effects on reporter gene activity (Fig. 1A). From the further chromatographic purification of fraction 9, we isolated an inhibitor of Wnt/β-catenin signaling pathway. The chemical structure was identified as 2,8-di-
methyl-6-hydroxy-2-(4-methyl-3-pentenyl)-2H-chromene (atracylochromene, AC) (Fig. 1B) by spectroscopic analysis and confirmed by comparison with the reported data (Resch et al., 1998).

**AC inhibits TOPFlash reporter activity**

As shown in Fig. 2A, treatment of AC inhibits TOPFlash activity in Wnt3a CM-treated stable reporter HEK-293 cells in a dose-dependent manner. The activity of TOPFlash, a negative control reporter with mutated β-catenin/TCF binding elements, was not altered by the treatment of AC and Wnt3a CM (data not shown). To test whether the GSK-3β was involved in the inhibition of β-catenin response transcription, we treated HEK cells with LiCl as an inhibitor of GSK-3β. AC treatment also inhibits TOPFlash activity in LiCl-treated HEK-293 cells (Fig. 2B).

**AC inhibits nuclear translocation of β-catenin in SW480 cells**

To further confirm the inhibitory effect of AC on Wnt/β-catenin signaling pathway, β-catenin constitutively activated SW-480 colon cancer cell line were used. Treatment of AC (20 µg/ml) decreased the nuclear level of β-catenin in SW-480 cells in a time-dependent manner. But the levels of β-catenin in cytosol and whole cell lysate were not affected by AC (Fig. 3A and 3B). And a target gene of β-catenin, cyclin D1 was decreased by treatment of AC in SW-480 cells. The level of galectin-3, one of the β-catenin nuclear translocation modulators, was also decreased in nuclear of AC-treated SW-480 cells, but not in cytosolic fraction and whole cell lysates (Fig. 3A, B). These data indicate that AC inhibits Wnt/β-catenin signaling pathway through modulating the nuclear translocation of β-catenin and galectin-3 in colon cancer cells.

**AC inhibits SW-480 cell proliferation**

As AC inhibits Wnt/β-catenin signaling pathway in SW-480 cells, we have tested the effects of AC on proliferation of colon cancer cells. As shown in Fig. 4, the cell viabilities of SW-480 cells were decreased dramatically by treatment of AC in a dose dependent manner ranging from 5 to 20 µg/ml. Taken together, AC inhibits Wnt/β-catenin signaling pathway to suppress proliferation of colon cancer cells, and galectin-3 is maybe involved in its action mechanism.

**DISCUSSION**

It has been reported that about 90% of Wnt/β-catenin signaling pathway is mutated in sporadic and hereditary colorectal cancers (Miyaki et al., 1994; Jemal et al., 2011). The mutated Wnt/β-catenin pathway causes to stabilize and abnormally activates β-catenin signal (Chen et al., 1995). The aberrant activation of β-catenin increases its translocation to nucleus (Kobayashi et al., 2000), and increases the expression of oncopigenic target gene, such as cyclin D1 (Tetsu and McCormick, 1999) in colorectal cancer. Thus, targeting of Wnt/β-catenin signaling pathway is a good strategy for developing new chemotherapeutic agents against colon cancer. We have tried to find new modulators of Wnt/β-catenin signaling pathway from medicinal plants by using cell-based reporter assay as
screening system. We purified an active compound from the ethyl acetate extracts of *A. macrocephala* and identified the structure as a branched chromene derivative, AC. AC inhibits TOPFlash activity in a dose-dependent manner (Fig. 2) and suppresses the expression of β-catenin target gene, cyclin D1 (Fig. 3B) in SW-480 colon cancer cells.

When Wnt pathway is activated, β-catenin can be released from the APC/Axin/GSK-3β destructive complex and translocated to the nucleus to activate expression of target genes. The nuclear translocation is regulated by several genes, such as FoxM1, importin/β, nucleoporins and galectin-3. Galectin-3 is associated with the development of several cancers including colorectal cancer (Song *et al*., 2014). Treatment of AC inhibits nuclear translocations of β-catenin and galectin-3 in SW-480 cells (Fig. 3A) to suppress β-catenin oncogenic target gene, cyclin D1. This parallel nuclear level of β-catenin and galectin-3 means that AC modulates nuclear translocation of β-catenin by using galectin-3 as a binding partner for translocation (Fig. 3). Galectin-3 was reported to accumulate β-catenin in human colon cancer by regulating GSK-3β activity (Song *et al*., 2009). An inhibitor of GSK-3β, LiCl can increase the nuclear accumulation of β-catenin through suppressing degradation of β-catenin in cytoplasm. AC significantly inhibits LiCl-induced TOPFlash activities, but not stronger than that observed in Wnt3a-induced system (Fig. 2B). Synthetic thiogalactosides (Delaine *et al*., 2008) and modified citrus pectin

![Fig. 3. Atractylochromene inhibits β-catenin signaling pathway in SW-480 cells. SW-480 cells were treated with 20 μg/ml of atractylochromene for the indicated time, and cells were harvested to prepare nuclear and cytosolic fractions (A), and whole cell lysates (B). Relative expression levels of target proteins were detected by western blot analysis.](image)

![Fig. 4. Atractylochromene inhibits SW-480 cell proliferation. SW-480 cells were treated with indicated dose of atractylochromene for the indicated time. Cell viability was measured by MTT assay. The asterisks indicate a significant difference from the vehicle treated group (*p<0.01.*](image)

![Fig. 5. Schematic diagram illustrating the proposed reaction point at which AC blocks the Wnt/β-catenin pathway in colon cancer cells.](image)
(Nangia-Makker et al., 2002) have been developed as specific inhibitors of galectin-3 to suppress cancers. Recent review summarized galectin-3 inhibitors and their application to cancer therapy (Blanchard et al., 2014; Nangia-Makker et al., 2007). Most of the reported galectin-3 inhibitors have carbohydrate-based structures and genistein was reported to induce cell cycle arrest in galectin-3 mediated manner (Lin et al., 2000). This is the first report on the galectin-3 mediated regulation of Wnt/beta-catenin signaling by plant-derived chromene compound. However, the exact regulation mechanism should be further investigated.

AC has been reported as anti-inflammatory and anti-oxidant agent (Resch et al., 1998; Li et al., 2012). AC also have inhibitory effects on 5-lipoxygenase and cyclooxygenase-1 activities (Resch et al., 1998). However, there is no report about effects of AC on colon cancer cell proliferation. In this study, we report that AC has inhibitory effects on colon cancer cell proliferation through inhibiting Wnt/beta-catenin signaling pathway and its target gene cyclin D1 expression (Fig. 4). In colon cancer, beta-catenin directly up-regulates cyclin D1 expression to promote proliferation of colon cancer cell (Tetsu and McCormick, 1999).

In conclusion, AC purified from A. macrocephala inhibits cyclin D1 expression through inhibiting nuclear translocation of beta-catenin and galectin-3 to inhibit colon cancer cell proliferation (Fig. 5). AC may be a new lead compound for the development of therapeutic agents against colon cancer through down-modulating Wnt/beta-catenin signaling pathway.

ACKNOWLEDGMENTS

This work was supported by Sookmyung Women’s University Research Grant in 2013.

REFERENCES


http://dx.doi.org/10.4062/biomolther.2014.095

30